Literature DB >> 17506994

A transgenic rat expressing human APP with the Swedish Alzheimer's disease mutation.

Ronnie Folkesson1, Katarzyna Malkiewicz, Ewa Kloskowska, Tatjana Nilsson, Elena Popova, Nenad Bogdanovic, Ursula Ganten, Detlev Ganten, Michael Bader, Bengt Winblad, Eirikur Benedikz.   

Abstract

In recent years, transgenic mice have become valuable tools for studying mechanisms of Alzheimer's disease (AD). With the aim of developing an animal model better for memory and neurobehavioural testing, we have generated a transgenic rat model of AD. These animals express human amyloid precursor protein (APP) containing the Swedish AD mutation. The highest level of expression in the brain is found in the cortex, hippocampus, and cerebellum. Starting after the age of 15 months, the rats show increased tau phosphorylation and extracellular Abeta staining. The Abeta is found predominantly in cerebrovascular blood vessels with very rare diffuse plaques. We believe that crossing these animals with mutant PS1 transgenic rats will result in accelerated plaque formation similar to that seen in transgenic mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17506994     DOI: 10.1016/j.bbrc.2007.04.195

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

2.  Continuous vaccinations of 4Aβ1-15 induces specific fluctuation of inflammatory factors accompany with pathologic alterations alleviation in APP/PS1 mice.

Authors:  Yuwei Zhang; Qingqing Li; Juntao Zou; Zejie Zuo; Zhibin Yao
Journal:  Hum Vaccin Immunother       Date:  2015-08-21       Impact factor: 3.452

3.  Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats.

Authors:  Rebecca F Rosen; Jason J Fritz; Jeromy Dooyema; Amarallys F Cintron; Tsuyoshi Hamaguchi; James J Lah; Harry LeVine; Mathias Jucker; Lary C Walker
Journal:  J Neurochem       Date:  2011-11-18       Impact factor: 5.372

Review 4.  Beyond the rat models of human neurodegenerative disorders.

Authors:  Ondrej Bugos; Mangesh Bhide; Norbert Zilka
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

5.  First-in-Rat Study of Human Alzheimer's Disease Tau Propagation.

Authors:  Tomas Smolek; Santosh Jadhav; Veronika Brezovakova; Veronika Cubinkova; Bernadeta Valachova; Petr Novak; Norbert Zilka
Journal:  Mol Neurobiol       Date:  2018-05-16       Impact factor: 5.590

Review 6.  Transgenic mouse models of Alzheimer's disease.

Authors:  Gregory A Elder; Miguel A Gama Sosa; Rita De Gasperi
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

Review 7.  APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.

Authors:  Leslie Crews; Edward Rockenstein; Eliezer Masliah
Journal:  Brain Struct Funct       Date:  2009-11-29       Impact factor: 3.270

8.  A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment.

Authors:  Li Liu; Ian J Orozco; Emmanuel Planel; Yi Wen; Alexis Bretteville; Pavan Krishnamurthy; Lili Wang; Mathieu Herman; Helen Figueroa; W Haung Yu; Ottavio Arancio; Karen Duff
Journal:  Neurobiol Dis       Date:  2008-04-07       Impact factor: 5.996

9.  Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are regulated tissue-specifically.

Authors:  Cansu Agca; Jason J Fritz; Lary C Walker; Allan I Levey; Anthony Ws Chan; James J Lah; Yuksel Agca
Journal:  BMC Neurosci       Date:  2008-02-26       Impact factor: 3.288

Review 10.  Alzheimer disease models and human neuropathology: similarities and differences.

Authors:  Charles Duyckaerts; Marie-Claude Potier; Benoît Delatour
Journal:  Acta Neuropathol       Date:  2007-11-16       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.